SNX 239

Drug Profile

SNX 239

Latest Information Update: 11 Nov 1998

Price : $50

At a glance

  • Originator Elan Pharmaceuticals
  • Class Analgesics; Antiepileptic drugs; Neuroprotectants
  • Mechanism of Action Calcium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Neuralgia

Most Recent Events

  • 11 Nov 1998 No-Development-Reported for Neuralgia in USA (Unknown route)
  • 18 Oct 1995 A study has been added to the pharmacodynamics section
  • 03 Oct 1995 Preclinical development for Neuralgia in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top